source
- Menarini's Stemline signs $1.1 billion deal to license Georgiamune's preclinical cancer immunotherapyGeorgiamune, a Maryland‑based immunology biotech, has granted Stemline Therapeutics, part of Italy's Menarini Group, exclusive worldwide rights to develop and commercialize its preclinical cancer c…
- Georgiamune to ship preclinical solid tumor drug to Menarini in deal up to $1.1 billionGeorgiamune, a small biotech based in Maryland, announced that it will supply its preclinical solid tumor candidate to Menarini, a family‑owned pharmaceutical company in Italy. The agreement is st…